

CSD/BM/SE/2025-2026

Date: March 6, 2026

To
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

To
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 530239

Scrip Symbol: SUVEN

Dear Sir/Madam,

Sub: Outcome of the Meeting of Board of Directors of Suven Life Sciences Limited held on March 6, 2026 – Allotment of 3,17,68,764 Equity Shares of the Company on preferential basis upon conversion 3,17,68,764 fully paid warrants

.....

With reference to the above subject and pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the Company at its meeting held today i.e. Friday, March 6, 2026 has approved conversion of 3,17,68,764 fully paid warrants and issued & allotted 3,17,68,764 (Three Crore Seventeen Lakhs Sixty Eight Thousand Seven Hundred Sixty four) Equity Shares of Rs.1/- each to the following Promoter group entity at an issue price of Rs. 134/- per share on preferential basis in accordance with SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.

Promoter entity	No. of Equity shares allotted
JASTI PROPERTY AND EQUITY HOLDINGS PRIVATE LIMITED (In its capacity as sole trustee of Jasti Family Trust)	3,17,68,764

Further it is informed that the Company has received from the above said allottee 100% consideration amount aggregating to Rs. 425,70,14,376/- in compliance with SEBI (ICDR) Regulations, 2018.

Consequently, the paid-up equity share capital of the company stands increased to the following:

Particulars	No. of Equity Shares	Amount in INR
Pre-issue subscribed & paid-up capital	231951819	23,19,51,819.00
Post-issue subscribed & paid-up capital	263720583	26,37,20,583.00

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
 Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
 Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com

Disclosure required pursuant to Regulation 30 and Schedule III of the SEBI (LODR) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, is enclosed herewith as **Annexure A**.

The Board Meeting commenced at 11:00 AM (IST) and concluded at 11:20 AM (IST).

Kindly take the same on record.

Thanking you.

Yours faithfully,

For **Suven Life Sciences Limited**

K. Sangeetha Laxmi

Company Secretary

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com

Annexure A

Disclosure of information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sl. no.	particulars	details						
a)	type of securities proposed to be issued (viz. equity shares, convertibles etc.);	Fully paid-up equity shares upon conversion of warrants						
b)	type of issuance (further public offering, rights issue, depository receipts (ADR/ GDR), qualified institutions placement, preferential allotment etc.);	Preferential Allotment in accordance with Chapter V of the SEBI (ICDR) Regulations, 2018 and other applicable law.						
c)	total number of securities proposed to be issued or the total amount for which the securities will be issued (approximately);	3,17,68,764 Equity Shares of face value of Rs. 1/- each pursuant to conversion of 3,17,68,764 warrants at an issue price of ₹ 134/- per warrant, for an aggregate consideration of Rs. 425,70,14,376/- to below allottee.						
d)	in case of preferential issue, the listed entity shall disclose the following additional details to the stock exchange(s):							
	i. number of investors;	1						
	ii. names of the investors;	<table border="1"> <thead> <tr> <th>Particulars</th> <th>No. of Equity Shares allotted</th> </tr> </thead> <tbody> <tr> <td>Promoter group entity</td> <td></td> </tr> <tr> <td>JASTI PROPERTY AND EQUITY HOLDINGS PRIVATE LIMITED (In its capacity as sole trustee of Jasti Family Trust)</td> <td>3,17,68,764</td> </tr> </tbody> </table>	Particulars	No. of Equity Shares allotted	Promoter group entity		JASTI PROPERTY AND EQUITY HOLDINGS PRIVATE LIMITED (In its capacity as sole trustee of Jasti Family Trust)	3,17,68,764
Particulars	No. of Equity Shares allotted							
Promoter group entity								
JASTI PROPERTY AND EQUITY HOLDINGS PRIVATE LIMITED (In its capacity as sole trustee of Jasti Family Trust)	3,17,68,764							
	iii. post allotment of securities - outcome of the subscription	Pursuant to conversion, the issued, subscribed and paid-up equity share capital of the Company stands increased to Rs. 26,37,20,583/- consisting of 26,37,20,583 fully paid-up equity shares of Rs. 1/- each.						
	iv. issue price/ allotted price (in case of convertibles)	Rs. 134/- per share						
	v. in case of convertibles - intimation on conversion of securities or on lapse of the tenure of the instrument;	Allotment of 3,17,68,764 equity shares pursuant to the conversion of warrants at an issue price of Rs. 134/- each (face value of Rs. 1/- each and premium of Rs. 133/- each) upon receipt of 100% consideration amount from above mentioned allottee amounting to Rs. 425,70,14,376/-						
e)	any cancellation or termination of proposal for issuance of securities including reasons thereof.	Not applicable						

Suven Life Sciences Limited